RedHill Biopharma Ltd.
RHB-204
Crohn's disease
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for RHB-204 in Crohn's disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“New RHB-204 in vitro data, from both spot and phage assays, demonstrated comparable MAP killing to RHB-104 4 . Importantly, MAP killing efficacy was achieved with lower doses of two of the active ingredients compared to RHB-104, indicative ”